Literature DB >> 12443657

A novel TB vaccine; towards a strategy based on our understanding of BCG failure.

E M Agger1, P Andersen.   

Abstract

The protection afforded by the currently available tuberculosis vaccine, bacillus Calmette-Guérin (BCG) is insufficient and new vaccine strategies are urgently needed. Progress in our understanding of the immunological deficits of BCG combined with novel knowledge on genetics of mycobacteria has paved the way for promising new vaccine strategies. These include recombinant modified BCG vaccines, attenuated strains of Mycobacterium tuberculosis, and various non-live candidates such as DNA and subunit vaccines. Decisive for transforming technical progress into a novel tuberculosis (TB) vaccine strategy is the recent advance in our understanding of the failure of BCG in the third world and the interaction between this vaccine and environmental mycobacteria.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12443657     DOI： 10.1016/s0264-410x(02)00447-4

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  14 in total

1.  Mucosal vaccination against tuberculosis using inert bioparticles.

Authors:  Rajko Reljic; Laura Sibley; Jen-Min Huang; Ilaria Pepponi; Andreas Hoppe; Huynh A Hong; Simon M Cutting
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

2.  Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice.

Authors:  Jiu ling Wang; Ya qing Qie; Bing dong Zhu; Hong mei Zhang; Ying Xu; Qing zhong Wang; Jia zhen Chen; Wei Liu; Hong hai Wang
Journal:  Med Microbiol Immunol       Date:  2008-05-20       Impact factor: 3.402

3.  Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 T cell epitopes.

Authors:  A S Hammond; M R Klein; T Corrah; A Fox; A Jaye; K P McAdam; R H Brookes
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

4.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

5.  Construction, expression and identification of a recombinant BCG vaccine encoding human Mycobacterium tuberculosis heat shock protein 65.

Authors:  Wuxing Dai; Liang Liang; Hong Gao; Hailang Huang; Zhihao Chen; Jizhong Cheng; Yongmu Huangfu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

Review 6.  Current efforts and future prospects in the development of live mycobacteria as vaccines.

Authors:  Tony W Ng; Noemí A Saavedra-Ávila; Steven C Kennedy; Leandro J Carreño; Steven A Porcelli
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

Review 7.  Manipulation of BCG vaccine: a double-edged sword.

Authors:  V K Singh; R Srivastava; B S Srivastava
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-25       Impact factor: 3.267

8.  A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

Authors:  Michael V Tullius; Günter Harth; Sasa Maslesa-Galic; Barbara J Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2008-08-25       Impact factor: 3.441

9.  Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model.

Authors:  Alberto R Cervantes-Villagrana; Rogelio Hernández-Pando; Arya Biragyn; Julio Castañeda-Delgado; Monica Bodogai; Margarita Martínez-Fierro; Eduardo Sada; Valentin Trujillo; Antonio Enciso-Moreno; Bruno Rivas-Santiago
Journal:  Vaccine       Date:  2012-11-26       Impact factor: 3.641

Review 10.  Current and novel approaches to vaccine development against tuberculosis.

Authors:  Mark J Cayabyab; Lilia Macovei; Antonio Campos-Neto
Journal:  Front Cell Infect Microbiol       Date:  2012-12-06       Impact factor: 5.293
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.